Curated News
By: NewsRamp Editorial Staff
September 09, 2025
VolitionRx Partners with Werfen to Advance APS Diagnostic Testing
TLDR
- VolitionRx's partnership with Werfen provides exclusive commercial rights to leverage their Nu.Q NETs assay for APS testing, potentially capturing a significant market advantage.
- VolitionRx's Nu.Q NETs assay detects neutrophil extracellular traps on Werfen's ACL AcuStar platform to identify thrombosis risk in antiphospholipid syndrome patients through clinical validation.
- This collaboration could improve diagnosis and monitoring for 4 million APS patients worldwide, enabling better disease management and potentially saving lives through earlier detection.
- VolitionRx's epigenetic technology represents the first CE-IVD biomarker being investigated for APS, offering a novel approach to understanding this complex autoimmune disorder.
Impact - Why it Matters
This collaboration represents a significant advancement in autoimmune disease diagnostics that could transform how antiphospholipid syndrome is detected and managed. For the approximately 4 million people affected by APS worldwide, this partnership could lead to earlier and more accurate diagnosis, better thrombosis risk assessment, and improved treatment monitoring. Current APS diagnosis requires two positive antibody tests weeks apart, creating diagnostic delays that this new biomarker approach could eliminate. The potential for improved patient outcomes through earlier intervention and better disease management makes this development crucial for both patients and healthcare providers in the autoimmune disease space.
Summary
VolitionRx Ltd. (NYSE American: VNRX), a multi-national epigenetics company, has entered into a Research License and Exclusive Commercial Option Rights Agreement with Werfen's Immunoassay Technology Center to evaluate antiphospholipid syndrome (APS) using Volition's proprietary Nu.Q H3.1 Neutrophil Extracellular Traps (NETs) assay on Werfen's diagnostic platforms. This strategic partnership leverages Werfen's expertise in specific diseases, product development, regulatory experience, and installed base of proprietary analyzers, as highlighted by Gael Forterre, Volition's Chief Commercial Officer.
The collaboration has already achieved a significant milestone with the successful transfer of the Nu.Q NETs assay to Werfen's ACL AcuStar platform. Early results in detecting NETs levels in APS patients are described as encouraging by Marta Palicio, Werfen's Immunoassay Technology Center Innovation R&D Director. The companies plan to conduct further validation and complete a clinical utility study to determine the marker's potential role as a risk indicator of thrombosis in APS patients, which could lead to better management of this complex autoimmune disorder affecting approximately 4 million people worldwide.
Volition believes its Nu.Q NETs test represents the first CE-IVD biomarker being investigated for APS, potentially revolutionizing diagnosis and monitoring of this condition that currently requires two positive antibody tests at least 12 weeks apart for diagnosis. This partnership exemplifies Volition's strategy to license its proprietary technology to large worldwide companies while maintaining its focus on advancing epigenetics science to improve early detection and monitoring of life-altering diseases through cost-effective blood tests.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, VolitionRx Partners with Werfen to Advance APS Diagnostic Testing
